KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Net Cash Flow: 2018-2025

Historic Net Cash Flow for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $3.3 million.

  • Castle Biosciences' Net Cash Flow fell 64.60% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.4 million, marking a year-over-year decrease of 351.69%. This contributed to the annual value of $20.9 million for FY2024, which is 186.56% up from last year.
  • As of Q3 2025, Castle Biosciences' Net Cash Flow stood at $3.3 million, which was up 144.57% from -$7.5 million recorded in Q2 2025.
  • Over the past 5 years, Castle Biosciences' Net Cash Flow peaked at $24.8 million during Q4 2024, and registered a low of -$139.0 million during Q3 2022.
  • For the 3-year period, Castle Biosciences' Net Cash Flow averaged around -$3.4 million, with its median value being -$4.7 million (2023).
  • Per our database at Business Quant, Castle Biosciences' Net Cash Flow tumbled by 2,592.48% in 2022 and then soared by 301.83% in 2024.
  • Castle Biosciences' Net Cash Flow (Quarterly) stood at -$33.5 million in 2021, then soared by 66.52% to -$11.2 million in 2022, then skyrocketed by 167.82% to $7.6 million in 2023, then skyrocketed by 224.89% to $24.8 million in 2024, then crashed by 64.60% to $3.3 million in 2025.
  • Its last three reported values are $3.3 million in Q3 2025, -$7.5 million for Q2 2025, and -$30.0 million during Q1 2025.